ALDER BIOPHARMACEUTICALS INC Contracts & Agreements
83 Contracts & Agreements
- Business Finance (21 contracts)
- Business Operations (10)
- Human Resources (20)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (5)
- Uncategorized (24)
- Second Supplemental Indenture, dated October 22, 2019, among Alder BioPharmaceuticals, Inc., Lundbeck LLC, and U.S. Bank National Association (Filed With SEC on October 22, 2019)
- Letter Agreement, dated October 21, 2019, between Robert W. Azelby and Alder BioPharmaceuticals, Inc (Filed With SEC on October 22, 2019)
- Alder BioPharmaceuticals, Inc. Executive Severance Benefit Plan, effective October 18, 2019 (Filed With SEC on October 22, 2019)
- Agreement and Plan of Merger, dated September 16, 2019, by and among Alder BioPharmaceuticals, Inc., H. Lundbeck A/S, Lundbeck LLC and Violet Acquisition Corp (Filed With SEC on September 16, 2019)
- 2018 Inducement Award Plan, as Amended and Restated (Filed With SEC on August 6, 2019)
- Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for the 2018 Inducement Award Plan (Filed With SEC on August 6, 2019)
- Form of Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (for Annual Grants) (Filed With SEC on August 6, 2019)
- Form of Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (for Initial Grants) (Filed With SEC on August 6, 2019)
- Transition and Consulting Agreement between Alder BioPharmaceuticals, Inc. and John A. Latham, Ph.D. dated March 28, 2019 (Filed With SEC on May 2, 2019)
- Compensation Information for Non-Employee Directors (Filed With SEC on May 2, 2019)
- Registration Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers listed on the Schedule of Buyers thereto, dated March 4, 2019 (Filed With SEC on March 5, 2019)
- Underwriting Agreement, dated February 27, 2019 (Filed With SEC on March 1, 2019)
- Common Stock Purchase Agreement, dated February 26, 2019, by and between Alder BioPharmaceuticals, Inc., Redmile Group, LLC and certain institutional and other accredited... (Filed With SEC on March 1, 2019)
- Transition Agreement between Alder BioPharmaceuticals, Inc. and Elisabeth A. Sandoval, dated November 2, 2018 (Filed With SEC on February 25, 2019)
- Offer Letter between Alder BioPharmaceuticals, Inc. and Carlos E. Campoy dated December 4, 2018 (Filed With SEC on February 25, 2019)
- Amendment to Offer Letter between Alder BioPharmaceuticals, Inc. and Carlos E. Campoy dated February 7, 2019. X 10.32+ Amended and Restated Executive Severance Benefit Plan (Filed With SEC on February 25, 2019)
- Amendment No: 1 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective September 19, 2016 (Filed With SEC on February 25, 2019)
- Amendment No: 2 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective November 17, 2016 (Filed With SEC on February 25, 2019)
- Amendment No: 3.1 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective December 22, 2017 (Filed With SEC on February 25, 2019)
- Amendment No: 4 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective June 15, 2018 (Filed With SEC on February 25, 2019)
- Amendment No. 5 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective January 1, 2019 (Filed With SEC on February 25, 2019)
- Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective May 4, 2015 (Filed With SEC on February 25, 2019)
- Quality Agreement on Manufacturing and Testing of Bulk Drug Substance between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective July 27, 2018 (Filed With SEC on February 25, 2019)
- Distribution Agreement, dated January 4, 2019, by and between Alder BioPharmaceuticals, Inc. and J.P. Morgan Securities LLC (Filed With SEC on January 4, 2019)
- Amendment to Separation and Consulting Agreement with Randy Schatzman dated September 12, 2018 (Filed With SEC on November 5, 2018)
- Offer Letter between the Company and Robert W. Azelby dated June 4, 2018 (Filed With SEC on August 7, 2018)
- Form of Amendment to Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (Filed With SEC on August 7, 2018)
- Form of Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (For awards after June 14, 2018) (Filed With SEC on August 7, 2018)
- Form of Restricted Stock Unit Award Grant Notice and Option Agreement (Time-Based Vesting) for the 2014 Equity Incentive Plan (Filed With SEC on August 7, 2018)
- Form of Restricted Stock Unit Award Grant Notice and Option Agreement (Performance-Based Vesting) for the 2014 Equity Incentive Plan (Filed With SEC on August 7, 2018)
- 2018 Inducement Award Plan (Filed With SEC on August 7, 2018)
- Form of Stock Option Grant Notice and Option Agreement (Time-Based Vesting) for the 2018 Inducement Award Plan (Filed With SEC on August 7, 2018)
- Form of Stock Option Grant Notice and Option Agreement (Performance-Based Vesting) for the 2018 Inducement Award Plan (Filed With SEC on August 7, 2018)
- Settlement and License Agreement, by and between the Company, AlderBio Holdings, LLC and Teva Pharmaceuticals International GmbH, dated January 5, 2018 (Filed With SEC on May 8, 2018)
- Separation and Consulting Agreement between the Company and Randall C. Schatzman dated March 26, 2018 (Filed With SEC on May 8, 2018)
- Offer Letter between the Company and Paul B. Cleveland dated March 18, 2018 (Filed With SEC on May 8, 2018)
- Offer Letter between the Company and Erin Lavelle dated March 17, 2018 (Filed With SEC on May 8, 2018)
- Separation and Consulting Agreement between Alder BioPharmaceuticals, Inc. and Timothy M. Whitaker, M.D., dated June 3, 2016 (Filed With SEC on February 26, 2018)
- Amendment to Offer Letter between Alder BioPharmaceuticals, Inc., and Elisabeth A. Sandoval, dated January 2, 2018 (Filed With SEC on February 26, 2018)
- Underwriting Agreement, dated January 29, 2018 (Filed With SEC on February 1, 2018)
- Base Indenture, dated February 1, 2018, between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on February 1, 2018)
- First Supplemental Indenture, dated February 1, 2018, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.50% convertible senior notes due... (Filed With SEC on February 1, 2018)
- Registration Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers listed on the Schedule of Buyers thereto, dated January 12, 2018 (Filed With SEC on January 19, 2018)
- Preferred Stock Purchase Agreement by and among Alder BioPharmaceuticals, Inc. and the Buyers set forth therein dated January 7, 2018 (Filed With SEC on January 11, 2018)
- Underwriting Agreement, dated July 12, 2017 (Filed With SEC on July 14, 2017)
- Alder BioPharmaceuticals, Inc. Executive Severance Benefit Plan (Filed With SEC on February 23, 2017)
- FIFTH AMENDMENT TO LEASE (Filed With SEC on November 21, 2016)
- ALDER BIOPHARMACEUTICALS, INC. 5,376,344 Shares of Common Stock Underwriting Agreement (Filed With SEC on April 8, 2016)
- FOURTH AMENDMENT TO LEASE (Filed With SEC on February 23, 2016)
- 4,494,382 Shares ALDERBIOPHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on June 26, 2015)
- [ ] Shares ALDER BIOPHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on December 22, 2014)
- Additional abbreviations mayalso be used though not in the above list. (Filed With SEC on December 22, 2014)
- ALDER BIOPHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 31, 2014 APPROVED BY THE STOCKHOLDERS:APRIL 7, 2014 (Filed With SEC on May 1, 2014)
- COLLABORATION AND LICENSE AGREEMENT Among ALDERBIOHOLDINGS LLC, ALDER BIOPHARMACEUTICALS INC. and BRISTOL-MYERSSQUIBB COMPANY (Filed With SEC on May 1, 2014)
- ADDENDUM NO. 1 TOCOLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 1, 2014)
- MASTER SERVICES AGREEMENT (Filed With SEC on May 1, 2014)
- EXHIBIT B LICENSEAGREEMENT (Filed With SEC on May 1, 2014)
- Master Product Development and Clinical Supply Agreement (Filed With SEC on May 1, 2014)
- FIRST AMENDMENT TO MASTER PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on May 1, 2014)
- [ ] ALDER BIOPHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on April 25, 2014)
- ALDER BIOPHARMACEUTICALS, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on April 25, 2014)
- INDEMNITY AGREEMENT (Filed With SEC on April 25, 2014)
- ALDER BIOPHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 31, 2014 APPROVED BY THE STOCKHOLDERS:APRIL 7, 2014 IPO DATE/EFFECTIVE DATE: ,... (Filed With SEC on April 25, 2014)
- ALDER BIOPHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on April 25, 2014)
- ALDER BIOPHARMACEUTICALS, INC. EXECUTIVE SEVERANCE BENEFIT PLAN (Filed With SEC on April 25, 2014)
- Master Product Development and Clinical Supply Agreement (Filed With SEC on April 25, 2014)
- FIRST AMENDMENT TO MASTER PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on April 25, 2014)
- ALDER BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT April 16, 2012 TABLE OF CONTENTS (Filed With SEC on March 19, 2014)
- ALDER BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED 2005 STOCK PLAN (Filed With SEC on March 19, 2014)
- ALDER BIOPHARMACEUTICALS, INC. 2005 STOCK PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on March 19, 2014)
- ALDER BIOPHARMACEUTICALS, INC. EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITPLAN (Filed With SEC on March 19, 2014)
- COLLABORATION AND LICENSE AGREEMENT Among ALDERBIOHOLDINGS LLC, ALDER BIOPHARMACEUTICALS INC. and BRISTOL-MYERSSQUIBB COMPANY (Filed With SEC on March 19, 2014)
- ADDENDUM NO. 1 TOCOLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 19, 2014)
- MASTER SERVICES AGREEMENT (Filed With SEC on March 19, 2014)
- EXHIBIT B LICENSEAGREEMENT (Filed With SEC on March 19, 2014)
- EARLY ENTRY AGREEMENT (Filed With SEC on March 19, 2014)
- FIRST AMENDMENT TO LEASE (Filed With SEC on March 19, 2014)
- SECOND AMENDMENT TO LEASE (Filed With SEC on March 19, 2014)
- THIRD AMENDMENT TO LEASE (Filed With SEC on March 19, 2014)
- Alder BioPharmaceuticals July 19, 2005 (Filed With SEC on March 19, 2014)
- Alder BioPharmaceuticals July 19, 2005 (Filed With SEC on March 19, 2014)
- Alder BioPharmaceuticals July 19, 2005 (Filed With SEC on March 19, 2014)
- Alder BioPharmaceuticals July 19, 2005 (Filed With SEC on March 19, 2014)